Revenio Group Oyj - Decisions of general meeting

Revenio Group Corporation: Decisions by the Annual General Meeting

Revenio Group Corporation: Decisions by the Annual General Meeting

Revenio Group Corporation, Stock Exchange Release, March 20, 2018 at 18.45

Decisions  by the Annual  General Meeting of  Revenio Group Corporation on March
20, 2018

1. Financial statements, Board and Auditors

The  AGM confirmed the company's financial  statements for the financial year 1
January - 31 December 2017, and discharged the members of the Board of Directors
and the Managing Director from liability.

The  AGM decided that five members be elected  to the Board of Directors and re-
elected  Ari Kohonen,  Pekka Rönkä,  Kyösti Kakkonen,  Ann-Christine Sundell and
Pekka  Tammela as board members. In board  meeting held after the AGM, the Board
of Directors elected Pekka Rönkä as Chair of the Board.

The  AGM  decided  that  the  Chairman  of  the  Board  be entitled to an annual
emolument  of EUR 48,000 and the  other Board members to  an annual emolument of
EUR 24,000.

A  total of 40 per cent of Board members' emoluments will be settled in the form
of company shares, while 60 per cent will comprise a monetary payment.

The  AGM re-elected Deloitte Oy, Authorized Public Accountants, as the company's
auditors  with  Merja  Itäniemi,  Authorized  Public  Accountant,  acting as the
principal  auditor. The AGM  decided to pay  the auditors' fees  as invoiced and
approved by the company.

2. Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according
to which the profit for the financial period, EUR 4,929,308.74, will be added to
retained  earnings, and a dividend of EUR 0.78 per share will be paid. Dividends
will  be  paid  to  shareholders  who  have  been  registered  in  the company's
shareholder  register,  maintained  by  Euroclear  Finland  Ltd, by the dividend
record date on March 22, 2018. The dividend payment date is March 29, 2018.

3. Share issue without payment (Share Split)

The  AGM  decised  to  accept  the  Board's  proposal to issue new shares to the
shareholders  without payment  in proportion  to their  holdings so that two new
shares are issued for each share (share split). A total of 15.958.812 new shares
will  be  issued.  The  shares  shall  be  issued  to  the  shareholders who are
registered  in the list  of shareholders maintained  by Euroclear Finland Ltd on
the  record  day  of  the  share  issue  March 22, 2018. The share issue without
payment  shall be  executed in  the book-entry  system and  will not require any
actions  by the shareholders. The new shares will generate shareholder rights as
of  March 23, 2018 when they have been registered in the trade register. The new
shares  will not entitle their holders to  the dividend to be paid in accordance
with the Section 2 above.

4. Authorizing  the Board of Directors to decide to repurchase the Company's own
shares

Since  the share issue without payment mentioned  above was approved by the AGM,
the  AGM authorized  the Board  to make  the decision  to buy  back a maximum of
2,393.821 of  the  company's  own  shares  in  one or several tranches using the
Company's  non-restricted equity  capital. The  Company may  buy back  shares in
order  to develop  its capital  structure, finance  and implement  any corporate
acquisitions  or other  transactions, implement  share-based incentive plans, or
otherwise transfer or cancel them.

The  Company may buy back  shares in public trading  on marketplaces whose rules
and  regulations allow the Company  to trade in its  own shares. In such a case,
the  Company  buys  back  shares  through  a  directed  purchase,  that is, in a
proportion  other than  its shareholders'  holdings in  Company shares, with the
consideration  for the  shares based  on their  publicly quoted market price, in
such  a manner that the minimum price  of the purchased shares equals the lowest
market  price quoted  in public  trading during  the authorization  period, and,
similarly,  their highest price equals the highest market price quoted in public
trading during that period.

This  authorization will be valid until April 30, 2019. This authorization shall
supersede the buyback authorization granted at the AGM of March 22, 2017.

5.  Authorizing  the Board of  Directors to decide  on a share  issue and on the
granting  of stock  options and  other special  rights conferring entitlement to
shares

Since  the share issue without payment mentioned  above was approved by the AGM,
the  AGM  authorized  the  Board  to  decide  on  a  share issue of a maximum of
2,393,821 shares  or to grant special rights (including stock options) entitling
holders  to shares as referred to in  Chapter 10 Section 1 of the Companies Act,
in one or several tranches.

This  authorization  is  proposed  to  be  used  to  finance  and  implement any
prospective  corporate  acquisitions  or  other  transactions,  to implement the
company's  share-based incentive plans, or for  other purposes determined by the
Board.

The authorization is also proposed to grant the Board the right to decide on all
terms  and conditions  governing said  share issue  and the  granting of special
rights, including the subscribers or the grantees of said special rights and the
payable  consideration.  The  authorization  also  includes  the  right to waive
shareholders' pre-emptive subscription rights and covers the issue of new shares
and the transfer of any shares that may be held by the company.

This  authorization will be valid until April 30, 2019. This authorization shall
supersede  the authorization to decide  on a share issue  and on the granting of
special  rights  giving  entitlement  to  shares  granted  in  the  AGM of March
22, 2017.



REVENIO GROUP CORPORATION
Board of Directors

For further information, please contact:
CEO and President Timo Hildén
tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio  is a  Finnish, globally  operating health  technology corporation whose
worldwide   success  is  based  on  a  strongly  patented  intraocular  pressure
measurement  technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
through  preventive  health  care.  Revenio  seeks  vigorous  growth  in  health
technology.  Revenio  aims  to  develop  even  more efficient and easily adopted
methods  for the early-stage detection of  diseases with significance for public
health. The focus of Revenio's screening technology is on the early detection of
glaucoma,  osteoporosis, skin  cancer and  asthma, and  the monitoring  of these
during the treatment process.

In  2017, Revenio Group's net sales totaled EUR 26.8 million, with its operating
margin,  excluding  non-recurring  items,  standing  at  35.5 %.  Revenio  Group
Corporation is listed on Nasdaq Helsinki.

[]